- Home
- OLP vs ALT Comparison
OLP vs ALT Comparison
Compare OLP & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- ALT
- Stock Information
- Founded
- OLP 1982
- ALT 1997
- Country
- OLP United States
- ALT United States
- Employees
- OLP N/A
- ALT N/A
- Industry
- OLP Real Estate Investment Trusts
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- OLP Real Estate
- ALT Health Care
- Exchange
- OLP Nasdaq
- ALT Nasdaq
- Market Cap
- OLP 569.9M
- ALT 472.3M
- IPO Year
- OLP N/A
- ALT N/A
- Fundamental
- Price
- OLP $23.98
- ALT $5.76
- Analyst Decision
- OLP Strong Buy
- ALT Strong Buy
- Analyst Count
- OLP 1
- ALT 7
- Target Price
- OLP $28.00
- ALT $21.00
- AVG Volume (30 Days)
- OLP 43.6K
- ALT 2.2M
- Earning Date
- OLP 05-06-2025
- ALT 05-13-2025
- Dividend Yield
- OLP 7.46%
- ALT N/A
- EPS Growth
- OLP N/A
- ALT N/A
- EPS
- OLP 1.35
- ALT N/A
- Revenue
- OLP $92,152,000.00
- ALT $20,000.00
- Revenue This Year
- OLP $13.29
- ALT N/A
- Revenue Next Year
- OLP $4.66
- ALT N/A
- P/E Ratio
- OLP $17.91
- ALT N/A
- Revenue Growth
- OLP 3.31
- ALT N/A
- 52 Week Low
- OLP $22.32
- ALT $3.55
- 52 Week High
- OLP $30.45
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- OLP 45.39
- ALT 57.44
- Support Level
- OLP $22.67
- ALT $4.95
- Resistance Level
- OLP $24.75
- ALT $6.05
- Average True Range (ATR)
- OLP 0.57
- ALT 0.40
- MACD
- OLP 0.03
- ALT 0.11
- Stochastic Oscillator
- OLP 62.98
- ALT 69.42
About OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.